North America and Europe PEGylated Drugs Market to hit $10.5 bn by 2024

Sellbyville, DE -- (SBWire) -- 02/07/2019 --Global North America and Europe PEGylated Drugs Market set to exceed USD 10.5 billion by 2024; according to a new research report by Global Market Insights.

Increasing R&D investment of biotechnology & pharmaceutical companies to develop enhanced PEGylated drugs for treatment of various chronic diseases along with rising occurrence of chronic ailments in developed regions will propel PEGylated drugs market growth over the forecast period. Major advancements in biologics sector including advances in drug antibody conjugates, and immunotherapies will positively impact market growth. Moreover, rising incidences of chronic ailments and increasing death rates associated with cancer in Canada will propel industry growth. However, the side-effects associated with pegylated drugs along with drug failure will impede PEGylated drugs market growth over the forecast timeframe.

Request for a sample of this research report @ https://www.gminsights.com/request-sample/detail/2511

Company profiled in this report based on Business overview, Financial data, Product landscape, Strategic outlook & SWOT analysis:
- Roche
- AstraZeneca
- Pfizer
- Amgen
- Biogen
- Novo Nordisk
- UCB
- Merck KGaA

Cancer segment held over 60% of the overall market share in 2017 due to growing prevalence of the disease creating a demand for the development of effective drugs. Benefits offered by PEGylated drugs such as reduced proteolytic degradation along with minimized immunogenicity leading to enhanced therapeutic efficacy will propel market growth. Increasing areas of applications as well as rising adoption of PEGylated drugs to treat various types of cancer will stimulate business growth. Hepatitis segment size was USD 156 million in 2017 and is anticipated to follow a declining trend over the forecast period. However, increasing focus of industry players to develop pegylated drugs used for the treatment of such chronic conditions will contribute to market growth. For instance, launch of Pegasys drug used for treating Hepatitis C in adult patients will fuel market growth.

To understand the implications of the cancer segment in defining the North America and Europe PEGylated drugs market, in 2015 about 1.3 million or 26% of all deaths in Europe resulted from cancer, making it the second biggest cause of fatalities in the EU. The upsurge in cigarette smoking and pollution along with unhealthy dietary consumption among EU population is expected to increase the frequency cancer and other chronic diseases. Consequently, the advantages of PEGylated drugs in improving treatments has inspired a number of companies in the region to develop bio-conjugated drugs, strengthening the North America and Europe PEGylated drugs industry.

Elaborating on the significance of North America and Europe PEGylated drugs market, a slew of PEGylated drug delivery systems such as Neulasta, Onivyde and PEG intron are employed in various cancer treatments, with additional drugs in the pipeline or pending approvals. For instance, the U.S. Food and Drug Administration (FDA) accepted a biologics license application from Shire PLC, a biotech leader in rare diseases, for Calaspargase Pegol (Cal-PEG) as a component of antineoplastic combination therapy for acute lymphoblastic leukemia (ALL) patients. The development is based on Shire's research and experience with ONCASPAR (pegaspargase), a first-line treatment for ALL approved in the U.S. According to reports on the efficiency and safety of Cal-PEG, if approved it will permit availability of treatments that have a prolonged shelf life beyond the current PEGylated asparaginase treatment.

Make an inquiry for purchasing this report @ https://www.gminsights.com/inquiry-before-buying/2511

The advent of PEGylation to increase the power and life of drug induced therapies can be justified by explaining the impact of acute lymphoblastic leukemia (ALL). ALL is technically a cancer of the white blood cells, which leads to excess lymphoblasts in the blood, bone marrow and other locations in the body. The American Cancer Society estimates that the risk of developing the disease is highest among children below 5 years of age, which declines gradually by the mid-20s and then arises again after the age of 50. Further, ALL accounts for close to 75% of the overall leukemia cases in U.S. children and up to 78% for the children in Europe. As such, the obligation to produce potent medicines for combination therapeutic treatments has driven the North America and Europe PEGylated drugs industry.

Chapter 3. North America & Europe PEGylated Drugs Industry Insights
3.1. Industry segmentation
3.2. Industry impact forces

3.2.1. Growth drivers
3.2.1.1. Increasing prevalence of cancer in developed regions
3.2.1.2. Rising R&D spending by biotechnology & pharmaceutical companies in U.S. and Europe
3.2.1.3. Growing biologics sector in the developed economies

3.2.2. Industry pitfalls & challenges
3.2.2.1. Drug recalls in the U.S. & Europe
3.2.2.2. Adverse drug reactions

3.4. Regulatory landscape
3.4.1. U.S.
3.4.2. Europe